VALBIOTIS announces positive preclinical results for the active ingredient in VAL-63-NAFLD on non-alcoholic fatty liver (NAFL), a risk factor for NASH.
Metformin + TOTUM-63 combination: first positive preclinical data for possible use in diabetes real life practiceDecember 4th 2017
VALBIOTIS announces first positive preclinical data on the combination of TOTUM-63 and metformin, for possible use in diabetes real life practice
VALEDIA®: launch of “pivotal” REVERSE-IT clinical trial to obtain a health claimNovember 8th 2017
VALBIOTIS announces that it has received authorization from the ANSM for the “pivotal” REVERSE-IT international clinical trial evaluating the efficacy of VALEDIA® against risk factors for type 2 diabetes in pre diabetic subjects.
LIPIDRIVE®: efficacy confirmed in three models, finalization of recruitment for Phase I/II in humansOctober 16th 2017
VALBIOTIS announces the efficacy of LIPIDRIVE® is confirmed in three preclinical models and the recruitment for Phase I/II, first study in humans, is being finalized.